Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study
Articolo
Data di Pubblicazione:
2019
Abstract:
Objective: To evaluate the subsequent rate of thrombosis among women with obstetric antiphospholipid syndrome (Ob-APS) in a multicentre database of antiphospholipid antibody (aPL)-positive patients, and the clinical utility of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS), a validated tool to assess the likelihood of developing new thrombosis, in this group of patients. Design: Retrospective study. Setting: The Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository. Population: Women with Ob-APS. Methods: Comparison of clinical and laboratory characteristics and measurement of aGAPSS in women with Ob-APS, with or without thrombosis, after initial pregnancy morbidity (PM). Main outcome measures: Risk factors for thrombosis and aGAPSS. Results: Of 550 patients, 126 had Ob-APS; 74/126 (59%) presented with thrombosis, and 47 (63%) of these women developed thrombosis after initial PM, in a mean time of 7.6 ± 8.2 years (4.9/100 patient years). Younger age at diagnosis of Ob-APS, additional cardiovascular risk factors, superficial vein thrombosis, heart valve disease, and multiple aPL positivity increased the risk of first thrombosis after PM. Women with thrombosis after PM had a higher aGAPSS compared with women with Ob-APS alone [median 11.5 (4–16) versus 9 (4–13); P = 0.0089]. Conclusion: Based on a retrospective analysis of our multicentre aPL database, 63% of women with Ob-APS developed thrombosis after initial obstetric morbidity; additional thrombosis risk factors, selected clinical manifestations, and high-risk aPL profile increased the risk. Women with subsequent thrombosis after Ob-APS had a higher aGAPSS at entry to the registry. We believe that aGAPSS is a valid tool to improve risk stratification in aPL-positive women. Tweetable abstract: More than 60% of women with obstetric antiphospholipid syndrome had thrombosis after initial pregnancy morbidity.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Antiphospholipid antibodies; antiphospholipid syndrome; fetal death; miscarriage; pre-eclampsia; thrombosis; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Clinical Trials as Topic; Databases, Factual; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Registries; Retrospective Studies; Risk Factors; Thrombosis
Elenco autori:
de Jesus, G. R.; Sciascia, S.; Andrade, D.; Barbhaiya, M.; Tektonidou, M.; Banzato, A.; Pengo, V.; Ji, L.; Meroni, P. L.; Ugarte, A.; Cohen, H.; Branch, D. W.; Andreoli, L.; Belmont, H. M.; Fortin, P. R.; Petri, M.; Rodriguez, E.; Cervera, R.; Knight, J. S.; Atsumi, T.; Willis, R.; Nascimento, I. S.; Rosa, R.; Erkan, D.; Levy, R. A.
Link alla scheda completa:
Pubblicato in: